Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: The study of muraglitazar and adverse events by Dr Nissen and colleagues1 points out why physicians need hard outcomes data obtained in a blinded fashion before prescribing a new therapy for patients. The study, however, raises broader concerns beyond muraglitazar. Mortality data are needed prior to US Food and Drug Administration (FDA) approval for peroxisome proliferator–activated receptor (PPAR) agonists, and current practices that use combined therapy for patients with diabetes who have lipid abnormalities need to be examined.
Najman DM. Adverse Events Related to Muraglitazar Use in Diabetes. JAMA. 2006;295(17):1997-1998. doi:10.1001/jama.295.17.1997-a